Data / Drug companies / Neuraminidase Inhibitor
Neuraminidase Inhibitor drugs: 5 drugs from 39 companies in the FDA NDC directory
Neuraminidase Inhibitor is an FDA established pharmacologic class. The FDA National Drug Code Directory lists 126 products in this class from 39 companies, covering 5 drugs by generic name. The main marketing category is generic drugs (ANDA), and the newest product started marketing on October 9, 2026.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- 39Companies
- 126Products
- 5Drugs by generic name
Drugs in the Neuraminidase Inhibitor class
Ranked by number of companies that list the drug.
| Drug | Products here | Companies listing it |
|---|---|---|
| Oseltamivir phosphate | 106 | 37 |
| Oseltamivir | 14 | 5 |
| Oseltamavir phosphate | 3 | 2 |
| Zanamivir | 2 | 2 |
| Oseltamivir acid | 1 | 1 |
Companies with the most products in this class
| Company | Products | Main dosage forms | Main marketing category | Newest product started |
|---|---|---|---|---|
| A-S Medication Solutions | 8 | capsule; powder, for suspension | Generic drugs (ANDA) | July 13, 2023 |
| Proficient Rx LP | 8 | capsule; powder, for suspension | Generic drugs (ANDA) | October 5, 2018 |
| Preferred Pharmaceuticals Inc. | 6 | capsule; for suspension | Generic drugs (ANDA) | January 28, 2026 |
| Sportpharm LLC | 6 | capsule | Generic drugs (ANDA) | October 8, 2018 |
| Asclemed USA, Inc. | 5 | capsule; powder, for suspension | Generic drugs (ANDA) | October 5, 2018 |
| Alembic Pharmaceuticals Inc. | 4 | capsule; for suspension | Generic drugs (ANDA) | June 29, 2026 |
| Alembic Pharmaceuticals Limited | 4 | capsule; for suspension | Generic drugs (ANDA) | June 29, 2026 |
| Alvogen Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | November 1, 2017 |
| Amneal Pharmaceuticals NY LLC | 4 | capsule; for suspension | Generic drugs (ANDA) | March 5, 2018 |
| Epic Pharma, LLC | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | August 2, 2022 |
| Exelan Pharmaceuticals Inc. | 4 | capsule; for suspension | Generic drugs (ANDA) | December 1, 2023 |
| Lannett Company, Inc. | 4 | capsule; suspension | Generic drugs (ANDA) | July 13, 2023 |
| Lupin Pharmaceuticals, Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | February 21, 2018 |
| Novadoz Pharmaceuticals LLC | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | May 6, 2022 |
| NuCare Pharmaceuticals,Inc. | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | May 28, 2020 |
| Redpharm Drug | 4 | capsule | Generic drugs (ANDA) | May 15, 2023 |
| Strides Pharma Science Limited | 4 | capsule; powder, for suspension | Generic drugs (ANDA) | October 24, 2022 |
| Zydus Lifesciences Limited | 4 | capsule; suspension | Generic drugs (ANDA) | August 5, 2021 |
| Zydus Pharmaceuticals USA Inc. | 4 | capsule; for suspension | Generic drugs (ANDA) | September 14, 2017 |
| Amneal Pharmaceuticals NY LLC | 3 | capsule | Generic drugs (ANDA) | September 27, 2022 |
| AvKARE | 3 | capsule; for suspension | Generic drugs (ANDA) | August 26, 2019 |
| Genentech, Inc. | 3 | capsule; powder, for suspension | New drug applications (NDA) | March 21, 2011 |
| Laurus Labs Limited | 3 | capsule | Generic drugs (ANDA) | May 2, 2024 |
| Macleods Pharmaceuticals Limited | 3 | capsule | Generic drugs (ANDA) | September 21, 2017 |
| Remedyrepack Inc. | 3 | capsule | Generic drugs (ANDA) | October 9, 2026 |
| Shandong New Time Pharmaceutical Co., Ltd. | 3 | capsule | Generic drugs (ANDA) | July 9, 2025 |
| Zhejiang Poly Pharm. Co., Ltd. | 3 | capsule | Generic drugs (ANDA) | December 31, 2025 |
| Proficient Rx LP | 2 | capsule | Generic drugs (ANDA) | August 25, 2020 |
| Ajanta Pharma USA Inc. | 1 | for suspension | Generic drugs (ANDA) | May 28, 2020 |
| Aurobindo Pharma Limited | 1 | powder, for suspension | Generic drugs (ANDA) | May 10, 2024 |
| Camber Pharmaceuticals, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | March 28, 2022 |
| Cipla USA Inc. | 1 | for suspension | Generic drugs (ANDA) | January 16, 2023 |
| GlaxoSmithKline LLC | 1 | powder | New drug applications (NDA) | September 22, 1999 |
| Hec Pharm USA Inc. | 1 | suspension | Generic drugs (ANDA) | March 25, 2026 |
| Leading Pharma, LLC | 1 | suspension | Generic drugs (ANDA) | June 1, 2022 |
| MSN Laboratories Private Limited | 1 | capsule | Generic drugs (ANDA) | May 22, 2020 |
| Oryza Pharmaceuticals Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | October 19, 2025 |
| Slate Run Pharmaceuticals, LLC | 1 | capsule | Generic drugs (ANDA) | January 1, 2024 |
| Teva Pharmaceuticals USA, Inc. | 1 | powder, for suspension | Generic drugs (ANDA) | July 10, 2019 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Capsule | 93 | 73.8% |
| Powder, for suspension | 15 | 11.9% |
| For suspension | 11 | 8.7% |
| Suspension | 5 | 4% |
| Powder | 2 | 1.6% |
Updated November 6, 2026. Read from US Food and Drug Administration, National Drug Code Directory (openFDA). CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.